1-5 of 5
Yoko Nakatsuru
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Abstract A273: TAS-5567, a highly potent and selective inhibitor of SYK kinase, demonstrated antitumor activity in diffuse large B-cell lymphoma (DLBCL) cellsin vitro and in vivo.

Free
Hiroki Irie, Aki Kawagishi, Keiko Ishihara, Shingo Tsuji, Yoko Nakatsuru, Jiro Kuze, Naoko Fujino, Yoshio Ogino, Hideya Komatani, Teruhiro Utsugi
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2013) 12 (11_Supplement): A273.
https://doi.org/10.1158/1535-7163.TARG-13-A273
Published: 01 November 2013
View articletitled, Abstract A273: TAS-5567, a highly potent and selective inhibitor of SYK kinase, demonstrated antitumor activity in diffuse large B-cell lymphoma (DLBCL) cellsin vitro and in vivo.
Journal Articles

Abstract A272: Intermittent treatment with TAS-120, an irreversible FGFR inhibitor, is effective in tumors harboring a FGFR gene abnormality.

Free
Yoko Nakatsuru, Hiroaki Ochiiwa, Hiroshi Sootome, Hidenori Fujita, Akihiro Hashimoto, Yoshihiro Shibata, Masato Chiba, Yayoi Fujioka, Kazuhiro Yonekura, Hiroshi Hirai, Teruhiro Utsugi
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2013) 12 (11_Supplement): A272.
https://doi.org/10.1158/1535-7163.TARG-13-A272
Published: 01 November 2013
View articletitled, Abstract A272: Intermittent treatment with TAS-120, an irreversible FGFR inhibitor, is effective in tumors harboring a FGFR gene abnormality.
Journal Articles

Abstract A270: TAS-120, a highly potent and selective irreversible FGFR inhibitor, is effective in tumors harboring various FGFR gene abnormalities.

Free
Hiroaki Ochiiwa, Hidenori Fujita, Kimihiro Itoh, Hiroshi Sootome, Akihiro Hashimoto, Yayoi Fujioka, Yoko Nakatsuru, Nobuyuki Oda, Kazuhiko Yonekura, Hiroshi Hirai, Teruhiro Utsugi
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2013) 12 (11_Supplement): A270.
https://doi.org/10.1158/1535-7163.TARG-13-A270
Published: 01 November 2013
View articletitled, Abstract A270: TAS-120, a highly potent and selective irreversible FGFR inhibitor, is effective in tumors harboring various FGFR gene abnormalities.
Journal Articles

MK-2206, an Allosteric Akt Inhibitor, Enhances Antitumor Efficacy by Standard Chemotherapeutic Agents or Molecular Targeted Drugs In vitro and In vivo

Free
Hiroshi Hirai, Hiroshi Sootome, Yoko Nakatsuru, Katsuyoshi Miyama, Shunsuke Taguchi, Kyoko Tsujioka, Yoko Ueno, Harold Hatch, Pradip K. Majumder, Bo-Sheng Pan, Hidehito Kotani
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2010) 9 (7): 1956–1967.
https://doi.org/10.1158/1535-7163.MCT-09-1012
Published: 07 July 2010
View articletitled, MK-2206, an Allosteric Akt Inhibitor, Enhances Antitumor Efficacy by Standard Chemotherapeutic Agents or Molecular Targeted Drugs In vitro and In vivo
Open the PDF for MK-2206, an Allosteric Akt Inhibitor, Enhances Antitumor Efficacy by Standard Chemotherapeutic Agents or Molecular Targeted Drugs In vitro and In vivo in another window
Includes: Supplementary data
Journal Articles

MK-5108, a Highly Selective Aurora-A Kinase Inhibitor, Shows Antitumor Activity Alone and in Combination with Docetaxel

Free
Toshiyasu Shimomura, Shinichi Hasako, Yoko Nakatsuru, Takashi Mita, Koji Ichikawa, Tsutomu Kodera, Takumi Sakai, Tadahiro Nambu, Mayu Miyamoto, Ikuko Takahashi, Satomi Miki, Nobuhiko Kawanishi, Mitsuru Ohkubo, Hidehito Kotani, Yoshikazu Iwasawa
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2010) 9 (1): 157–166.
https://doi.org/10.1158/1535-7163.MCT-09-0609
Published: 12 January 2010
View articletitled, MK-5108, a Highly Selective Aurora-A Kinase Inhibitor, Shows Antitumor Activity Alone and in Combination with Docetaxel
Open the PDF for MK-5108, a Highly Selective Aurora-A Kinase Inhibitor, Shows Antitumor Activity Alone and in Combination with Docetaxel in another window
Includes: Supplementary data